IBB240920P76000
- 0.00
- 0.000.00%
iShares Biotechnology ETF Newsroom
BioAge Stock Rallies 29% Following Upsized $198M IPO
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Peeling Back The Layers: Exploring Argenx Through Analyst Insights
Argenx Analyst Ratings
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Tech Stocks Lead Rally
Biogen to End Sage Deal for Neuro Candidate
Roche, Biogen Kidney Disease Drug Hits Main Goal in Late-stage Study
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
IShares Nasdaq Biotechnology ETF Declares Quarterly Distribution of $0.2005
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
Amgen Stock Slips 3% Following Phase 3 Data for Rocatinlimab, Uplizna
Analyst Expectations For Amgen's Future
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
BioAge, Obesity Drug Developer, Upsizes Proposed IPO
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today
Amgen Analyst Ratings
Medpace, Fortrea Cut as Jefferies Reviews CROs Amid Biotech Headwinds
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market